-
Phase 3 trial of dual SGLT inhibitor significantly reduces cardiovascular risk in diabetic patients
Time of Update: 2021-09-20
The results of the SOLOIST trial showed that sotagliflozin reduced the absolute risk of composite cardiovascular endpoints in patients with type 2 diabetes with acute decompensated heart failure (HF) by 33%, with preserved ejection fraction (HFpEF) and reduced ejection fraction ( The results of HFrEF) patients were consistent, and the benefit was obvious within one month of receiving treatment .
-
Buchang Pharmaceutical's wholly-owned subsidiary obtained the notice of supplementary application for Tiangui menopause soft capsule drugs
Time of Update: 2021-09-20
("Shaanxi Buchang"), had recently received the "Tiangui Gengnian Soft Capsule" approved and issued by the State Drug Administration.
Tiangui Gengnian Soft Capsule has the functions of nourishing liver and kidney, promoting blood circulation and removing blood stasis .
-
Simcere Pharmaceuticals Announcement of Mid-2021 Results: Increased R&D Investment and Accelerated Innovation and Transformation
Time of Update: 2021-09-20
Simcere’s interim results report shows that: the central nervous system disease drug portfolio (main products must be new and must be stored) revenue reached 595 million yuan, accounting for 28.
-
Top 20 most influential pharmaceutical R&D executives in the world
Time of Update: 2021-09-20
John Leonard: the pioneer of gene editing LNP technologyJohn LeonardJohn Leonard was the senior vice president of global drug development at AbbVie and currently serves as the chief executive officer (CEO) of Intellia Therapeutics .
-
Merck's Centennial Art of War: Seeking innovation within the regulations to promote China's pharmaceutical "global voyage" stable and far-reaching
Time of Update: 2021-09-20
A grand strategy, a new vision . In recent years, China's pharmaceutical industry has developed rapidly, especially in 2017, when China announced its participation in the International Human Medicine
-
The CDK family is in full bloom. Dozens of domestic pharmaceutical companies have entered the track!
Time of Update: 2021-09-20
Today, Ibrance has grown into a blockbuster drug with annual sales of more than US$5 billion, followed by 3 CDK4/6 inhibitors in China; , Jiangsu Hengrui’s SHR-6390 has also entered the NDA stage.
-
Chen Jianming, deputy general manager of Pien Tze Huang, resigns after retirement
Time of Update: 2021-09-20
Chen Jianming reached the legal retirement age, he applied to the board of directors for retirement and resigned from the position of deputy general manager of the company .
Chen Jianming's resignation report will take effect from the day it is delivered to the company's board of directors .
-
Target PD-1 and LAG-3!
Time of Update: 2021-09-20
Text|Pharmaceutical Mission HillsThe Center for Drug Evaluation (CDE) of the National Medical Products Administration of China revealed that Roche's application for a new class 1 drug RO7247669 injection has obtained an implied license for a clinical trial and is intended to be developed for the treatment of liver cancer .
-
Nature: Prospects for the mRNA drug market in 2035
Time of Update: 2021-09-20
Taking into account the target population penetration rate, pricing and competition for the main indications, it is estimated that the average global peak sales of preventive mRNA vaccine drugs (products other than the COVID-19 vaccine) are about 800 million US dollars .
-
Bayer/Zhiben larotrectinib companion diagnostic reagent passed special review for innovative medical devices
Time of Update: 2021-09-20
On August 22, Zhiben Medical announced that the human NTRK1/2/3 gene mutation detection kit (reversible terminal termination sequencing method) has been awarded the "Special Review of Innovative Medical Devices" by the Medical Device Technology Evaluation Center of the State Drug Administration .
-
Jingxin Pharmaceutical signed an agreement with South Korea's B-PS Company to introduce JBPOS0101
Time of Update: 2021-09-20
According to the agreement, the company has obtained two clinical indications (infant spasm is in phase II clinical trials in the United States, and focal epilepsy has completed phase I clinical trials in the United States) in mainland China (including Hong Kong, Macau) exclusive clinical research and development, production and commercialization rights .
-
Bangyao Biological Appoints Ms. Li Fuying as Vice President & Head of Pharmaceutical Affairs Department
Time of Update: 2021-09-20
Li Fuying as the company's vice president & head of the pharmaceutical administration team, who will be responsible for the domestic and international registration of Bangyao's pipeline products .
-
The raw material drug Cetirizine Hydrochloride, a wholly-owned subsidiary of Warner Pharmaceuticals, passed the CDE approval
Time of Update: 2021-09-20
passed the CDE approval .
Cetirizine hydrochloride, the second-generation histamine H1 receptor antagonist (anti-allergic drug), is mainly used for respiratory, skin and eye allergic diseases, including perennial allergic diseases, such as allergic skin diseases, Look for measles, allergic rhinitis, itchy eyes, conjunctivitis and asthma .
-
Notice: The township health center is the main body to carry out rounds of consultations and stationed services
Time of Update: 2021-09-20
Visits: Qualified physicians in township hospitals should be selected, and if necessary, a round-trip team consisting of physicians, nurses, public health personnel, and auxiliary department personnel may be formed to carry out services .
-
Internet medical treatment actually gives drug rebates?
Time of Update: 2021-09-20
Good Doctor Online said that recently, Good Doctor received feedback from doctors online, claiming that an emerging Internet medical platform sent information to the doctor, inviting doctors to open the online platform, saying "The policy is: original research (drug) 5%-10%, domestically produced (Medicine) 10%-20% (commission), settled in the form of consulting fees, and does not calculate personal income tax .
-
JAK inhibitor approved for the first time for the treatment of eczema, upatinib received EU approval for the fourth indication
Time of Update: 2021-09-20
On August 24, 2021, AbbVie announced that the European Commission (EC) approved its oral JAK inhibitor upadacitinib (upadacitinib, English trade name Rinvoq) to expand its indications for the treatment of suitable systemic For adults and adolescents over 12 years of age with moderate/severe atopic dermatitis, they can choose whether to use it in combination with topical corticosteroids (TCS) .
-
Hebei Provincial Food and Drug Administration Publicly Solicits Opinions on the Implementation Rules for the Management of Chinese Medicine Formula Granules
Time of Update: 2021-09-20
Chapter 2 Production Management Article 5 A Chinese medicine manufacturer that produces Chinese medicine formula granules shall meet the following conditions: (1) Established in accordance with the law in China and able to independently assume responsibility (including the ability to assume responsibility for drug quality and safety) .
-
Hanyu Pharmaceutical Etibatide passed the consistency evaluation of generic drugs
Time of Update: 2021-09-20
To reduce the combined end-point rate of death, new myocardial infarction or the need for emergency interventional therapy .
-
Ningxia Hui Autonomous Region Food and Drug Administration Publicly Solicits Opinions on Management Rules of Chinese Medicine Formula Granules
Time of Update: 2021-09-20
On September 7, the Drug Administration of Ningxia Hui Autonomous Region issued a notice on the public solicitation of "Rules for the Management of Traditional Chinese Medicine Formula Granules in Nin
-
Three new anti-tumor drugs are planned to be included in breakthrough treatment varieties
Time of Update: 2021-09-20
Text|Pharmaceutical Mission HillsAccording to the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, three new anti-tumor drugs are planned to be included in breakthrough treatment products, which come from Haihe Pharmaceutical, Hutchison Medicine, and Five Prime Therapeutics under Amgen .
